Stocks · News reference
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Gainers CareDx (NASDAQ:CDNA) shares rose 22.2% to $87.42 during Friday's regular session. The company's market cap stands at $3.7 billion. As per the press release, Q3 earnings came out yesterday. Jin Medical
U.S. stocks fell Friday, with Nasdaq down 2.36% as Amazon missed Q3 estimates. Acumen plunged 85%, while oil rose 1.8% and gold fell 1.7%.
Acumen Pharmaceuticals is discontinuing the development of its lead clinical candidate, sabirnetug (ACU193), following the failure of a Phase 2 clinical trial to meet its primary endpoint.
Filed: 2026-10-30 AccNo: 0001628280-26-068425 Size: 215 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Acumen Pharmaceuticals reported Q3 2026 results with a net loss of $25.4 million and cash reserves of $78.6 million expected to support operations into early 2027. The company is preparing for November 2026 topline results from its Phase 2 ALTITUDE-AD trial testing sabirnetug for early Alzheimer's disease, with 542 participants enrolled. Management expects a 30% slowing of cognitive decline on the iADRS scale as the clinical success benchmark and anticipates low double-digit ARIA-E safety rates. The company is also advancing its Enhanced Brain Delivery program toward an IND filing in mid-2027.
Acumen Pharmaceuticals released its financial results and business updates for the third quarter of 2026.